月別アーカイブ: 2013年7月

Pharmacy Automation Solutions Help Hospitals Gain Control and Refocus on Clinical Care

ATLANTA–(BUSINESS WIRE)–

Jameson Health System, located north of Pittsburgh, has partnered with
McKesson Automation to implement a closed-loop pharmacy
automation solution
that helps support quality and patient care
while freeing pharmacy staff to focus on clinical care activities.

Building on its existing relationship with McKesson for pharmaceutical
distribution, Jameson plans to implement a full suite of central
pharmacy and point-of-care automation solutions. The new products will
help Jameson’s pharmacy to streamline workflow processes and reduce risk
through greater visibility into the entire medication management process.

“McKesson was the only company that could support our pharmacy
distribution model with a full solution set that will help us not only
lay the foundation for bedside scanning of patient medications today,
but also be flexible enough to adapt to our future needs,” explained Ron
Shollenberger, director of pharmacy, Jameson Health System.

McKesson Automation offers integrated pharmacy automation solutions that
help hospitals and health systems support improved patient outcomes,
build better businesses and manage ongoing change. With a deeper
understanding of medication management and a system-wide approach,
McKesson Automation helps health systems to better manage their pharmacy
operations and inventory more safely and efficiently.

At the point of care, Jameson is implementing AcuDose-Rx®
medication dispensing cabinets on patient floors, and it is
deploying Anesthesia-Rx
medication carts in the surgical suite. Designed to support quick, easy
access to medications, nurses and anesthesiology professionals have
fully embraced the new carts. “McKesson worked with us to gain a deeper
understanding of our processes and identify a solution that will
ultimately result in our staff having more time to focus on patient
care,” said Debra Perretta, RN, BSN, director, Quality, Jameson Health
System.

AcuDose-Rx cabinets feature the exclusive RightStock™ inventory
optimization functionality, which has been shown to reduce medication
stock outs by up to 70 percent and also reduce the number and instances
of expired medications. In addition, RightStock helps track medication
usage, enabling pharmacies to reclaim up to one-third of cabinet space
for fast-moving medications.

In the central pharmacy, Jameson is implementing PROmanager-Rx™.
This bar code-driven robotics system is designed to fully automate the
storage, dispensing, returns, and crediting of manufacturer-packaged,
oral-solid unit doses. As a result, pharmacies can increase filling
accuracy while reducing pharmacy labor. The MedCarousel®
storage and dispensing system will help support better inventory
management and improved productivity.

Jameson also plans to implement Fulfill-Rxsm,
an electronic data interchange between McKesson pharmaceutical
distribution centers and hospital automation solutions. Fulfill-Rx
expedites ordering and synchronization of key formulary information,
while bar-code-driven processes help reduce order receipt and restocking
time.

“Our integrated product portfolio supports accountability for
medications across the entire medication workflow, giving the pharmacy
visibility at every step in the process,” said Kraig McEwen, president
of McKesson Automation. “It enables us to help customers optimize what
they have in place today while strategically planning for the future.”

New partnerships like Jameson demonstrate the continued value of
McKesson distribution solutions and pharmacy automation solutions in
providing high quality, cost-effective and efficient solutions that
safely deliver the right medication closest to the patient.

About McKesson Corporation

McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a
healthcare services and information technology company dedicated to
making the business of healthcare run better. We partner with payers,
hospitals, physician offices, pharmacies, pharmaceutical companies and
others across the spectrum of care to build healthier organizations that
deliver better care to patients in every setting. McKesson helps its
customers improve their financial, operational, and clinical performance
with solutions that include pharmaceutical and medical-surgical supply
management, healthcare information technology, and business and clinical
services. For more information, visit www.mckesson.com.

About Jameson Health System

Jameson Health System is a not-for-profit healthcare provider located in
New Castle, Pennsylvania delivering a full spectrum of acute care
hospital services, surgical services and ambulatory care, outpatient
diagnostic services, long-term care and rehabilitative services and
physician-based clinic and office services. With more than 1,300
employees; over 250 physicians and nearly 25 facilities, JHS delivers
community healthcare on an expanding, regional landscape. For more
information, visit www.jamesonhealth.org.

Source Article from http://finance.yahoo.com/news/pharmacy-automation-solutions-help-hospitals-133500418.html
Pharmacy Automation Solutions Help Hospitals Gain Control and Refocus on Clinical Care
http://finance.yahoo.com/news/pharmacy-automation-solutions-help-hospitals-133500418.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo! News Search Results
pharmacy – Yahoo! News Search Results





Pharmacy Automation Solutions Help Hospitals Gain Control and Refocus on Clinical Care

ATLANTA–(BUSINESS WIRE)–

Jameson Health System, located north of Pittsburgh, has partnered with
McKesson Automation to implement a closed-loop pharmacy
automation solution
that helps support quality and patient care
while freeing pharmacy staff to focus on clinical care activities.

Building on its existing relationship with McKesson for pharmaceutical
distribution, Jameson plans to implement a full suite of central
pharmacy and point-of-care automation solutions. The new products will
help Jameson’s pharmacy to streamline workflow processes and reduce risk
through greater visibility into the entire medication management process.

“McKesson was the only company that could support our pharmacy
distribution model with a full solution set that will help us not only
lay the foundation for bedside scanning of patient medications today,
but also be flexible enough to adapt to our future needs,” explained Ron
Shollenberger, director of pharmacy, Jameson Health System.

McKesson Automation offers integrated pharmacy automation solutions that
help hospitals and health systems support improved patient outcomes,
build better businesses and manage ongoing change. With a deeper
understanding of medication management and a system-wide approach,
McKesson Automation helps health systems to better manage their pharmacy
operations and inventory more safely and efficiently.

At the point of care, Jameson is implementing AcuDose-Rx®
medication dispensing cabinets on patient floors, and it is
deploying Anesthesia-Rx
medication carts in the surgical suite. Designed to support quick, easy
access to medications, nurses and anesthesiology professionals have
fully embraced the new carts. “McKesson worked with us to gain a deeper
understanding of our processes and identify a solution that will
ultimately result in our staff having more time to focus on patient
care,” said Debra Perretta, RN, BSN, director, Quality, Jameson Health
System.

AcuDose-Rx cabinets feature the exclusive RightStock™ inventory
optimization functionality, which has been shown to reduce medication
stock outs by up to 70 percent and also reduce the number and instances
of expired medications. In addition, RightStock helps track medication
usage, enabling pharmacies to reclaim up to one-third of cabinet space
for fast-moving medications.

In the central pharmacy, Jameson is implementing PROmanager-Rx™.
This bar code-driven robotics system is designed to fully automate the
storage, dispensing, returns, and crediting of manufacturer-packaged,
oral-solid unit doses. As a result, pharmacies can increase filling
accuracy while reducing pharmacy labor. The MedCarousel®
storage and dispensing system will help support better inventory
management and improved productivity.

Jameson also plans to implement Fulfill-Rxsm,
an electronic data interchange between McKesson pharmaceutical
distribution centers and hospital automation solutions. Fulfill-Rx
expedites ordering and synchronization of key formulary information,
while bar-code-driven processes help reduce order receipt and restocking
time.

“Our integrated product portfolio supports accountability for
medications across the entire medication workflow, giving the pharmacy
visibility at every step in the process,” said Kraig McEwen, president
of McKesson Automation. “It enables us to help customers optimize what
they have in place today while strategically planning for the future.”

New partnerships like Jameson demonstrate the continued value of
McKesson distribution solutions and pharmacy automation solutions in
providing high quality, cost-effective and efficient solutions that
safely deliver the right medication closest to the patient.

About McKesson Corporation

McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a
healthcare services and information technology company dedicated to
making the business of healthcare run better. We partner with payers,
hospitals, physician offices, pharmacies, pharmaceutical companies and
others across the spectrum of care to build healthier organizations that
deliver better care to patients in every setting. McKesson helps its
customers improve their financial, operational, and clinical performance
with solutions that include pharmaceutical and medical-surgical supply
management, healthcare information technology, and business and clinical
services. For more information, visit www.mckesson.com.

About Jameson Health System

Jameson Health System is a not-for-profit healthcare provider located in
New Castle, Pennsylvania delivering a full spectrum of acute care
hospital services, surgical services and ambulatory care, outpatient
diagnostic services, long-term care and rehabilitative services and
physician-based clinic and office services. With more than 1,300
employees; over 250 physicians and nearly 25 facilities, JHS delivers
community healthcare on an expanding, regional landscape. For more
information, visit www.jamesonhealth.org.

Source Article from http://finance.yahoo.com/news/pharmacy-automation-solutions-help-hospitals-133500418.html
Pharmacy Automation Solutions Help Hospitals Gain Control and Refocus on Clinical Care
http://finance.yahoo.com/news/pharmacy-automation-solutions-help-hospitals-133500418.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo! News Search Results
pharmacy – Yahoo! News Search Results





Merz Pharma Group Acquires Swiss Dermatology Company Neocutis S.A.

GREENSBORO, N.C. & FRANKFURT, Germany–(BUSINESS WIRE)–

Merz Pharma Group (Frankfurt am Main) today announced that it has
entered into a definitive agreement with Swiss dermatology company
Neocutis S.A. to acquire the privately held company’s cosmetics, OTC,
and Rx skin care business. The acquisition of Neocutis strengthens
Merz’s market position in the field of aesthetics and reflects the
Company’s strategy to establish itself as a global leader in medical and
aesthetic dermatology.

“Neocutis is an innovative company with an excellent presence in the
U.S. market, and a promising potential for development,” said Philip
Burchard, CEO of Merz Pharma Group. “This transaction is an important
step to expand our U.S. business, as Neocutis products are an excellent
addition to our own aesthetics portfolio.”

The acquisition, which closed on July 22, 2013, will be managed in North
America by Merz Pharma Group’s U.S. affiliate, Merz North America, Inc.,
which will also integrate marketing of Neocutis’ line of
physician-dispensed topical skin care products in the U.S.

“The acquisition of Neocutis significantly strengthens Merz’s presence
in the U.S. aesthetics market,” said Bill Humphries, President and CEO
of Merz North America, Inc. “Neocutis’ line of topical skin care
products complements our current portfolio of aesthetic injectable
products and expands our ability to provide patients and physicians with
innovative, high-quality aesthetic products along the full continuum of
care. We are excited to welcome the Neocutis team to the Merz family; we
look forward to learning from them and seeing their contributions to our
continued growth in North America. We are proud to contribute to Merz’s
global leadership in aesthetic and medical dermatology, and we remain
committed to growing the U.S. business via both organic growth and
additional licensing and acquisition opportunities.”

In the U.S., Merz Pharma Group’s affiliate Merz North America is an
important contributor to the aesthetics space, offering a well-balanced
range of products for minimally invasive treatments, including the
dermal fillers Radiesse® Volumizing Filler and Belotero Balance®, the
neurotoxin Xeomin® (incobotulinumtoxinA), the Mederma® family of
products for scar care and stretch marks therapy and an injectable
product for the treatment of varicose veins.

Neocutis S.A. was founded in February 2003 as a spin-off of the medical
faculty of the Lausanne University Clinic, Switzerland. The privately
owned company is headquartered in Lausanne, Switzerland and develops and
distributes innovative cosmetic products for dermatologic conditions and
anti-aging skincare. The company entered the U.S. market in 2009 and
since that time has seen double-digit growth annually.

Following the acquisition, Merz North America plans to leverage
Neocutis’ existing preferred customer programs with the Merz Aesthetics™
product line to provide additional benefits to physicians and patients.

About Merz North America

Merz North America is a specialty healthcare company that develops and
commercializes innovative treatment solutions in medical and aesthetic
dermatology, and neurology in the U.S. and Canada. Our ambition is to
become a recognized leader in the treatment of movement disorders, and
in aesthetics and dermatology. Our future is promising, and we are
committed to advancing new therapeutic options and improving patients’
lives. For more than 100 years, the development of Merz products has
been based on our commitment to providing innovative medical approaches
that earn trust of patients, physicians and partners worldwide. For more
information about Merz or the Company’s products, please visit www.merzusa.com.

About the Merz Pharma Group

Merz’s business activities are in the research, development and
distribution of innovative pharmaceutical and medical products for
aesthetic and medical dermatology and the fields of neurology and
metabolic disorders. Memantine, the first active agent in the world with
a glutamatergeric effect for the treatment of moderate to severe
Alzheimer’s dementia, is the second most frequently prescribed
anti-dementive medication. For the treatment of neurological movement
disorders, Merz developed Xeomin® (incobotulinumtoxinA). Another core
competence of Merz is clinical and aesthetic dermatology. Merz
Aesthetics offers a well-balanced range of products for minimally
invasive treatments. With the fillers Radiesse® Volumizing Filler and
Belotero Balance® and the neurotoxin Xeomin® (incobotulinumtoxinA) the
company is an important contributor to the American aesthetic market.
With the brands tetesept® and Merz Spezial®, Merz Consumer Care is a
leading supplier of OTC medications, food supplements and skincare
products in German-speaking countries.

IMPORTANT SAFETY INFORMATION for XEOMIN®
(incobotulinumtoxinA)
INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of XEOMIN®
(incobotulinumtoxinA) for injection, for intramuscular use, and all
botulinum toxin products may spread from the area of injection to
produce symptoms consistent with botulinum toxin effects.
These
may include asthenia, generalized muscle weakness, diplopia, blurred
vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence
and breathing difficulties.
These symptoms have been reported
hours to weeks after injection.
Swallowing and breathing
difficulties can be life threatening and there have been reports of
death.
The risk of symptoms is probably greatest in children
treated for spasticity but symptoms can also occur in adults treated for
spasticity and other conditions, particularly in those patients who have
underlying conditions that would predispose them to these symptoms.
In
unapproved uses, including spasticity in children and adults, and in
approved indications, cases of spread of effect have been reported at
doses comparable to those used to treat cervical dystonia and at lower
doses.

Source Article from http://finance.yahoo.com/news/merz-pharma-group-acquires-swiss-120000130.html
Merz Pharma Group Acquires Swiss Dermatology Company Neocutis S.A.
http://finance.yahoo.com/news/merz-pharma-group-acquires-swiss-120000130.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo! News Search Results
pharma – Yahoo! News Search Results